ADX 1615
Alternative Names: ADX-1615Latest Information Update: 28 Jul 2022
At a glance
- Originator Aldeyra Therapeutics
- Class Antineoplastics; Immunotherapies; Small molecules
- Mechanism of Action HSP90 heat-shock protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders; Cancer
Most Recent Events
- 28 Jul 2022 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA (PO)
- 28 Jul 2022 No recent reports of development identified for preclinical development in Cancer in USA (PO)
- 17 Jul 2018 Aldeyra Therapeutics plans clinical trials for Cancer and Autoimmune disorders in 2020